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Context: Insulin autoimmune syndrome (IAS), spontaneous hyperinsulinemic hypoglycemia 
due to insulin-binding autoantibodies, may be difficult to distinguish from tumoral or other 
forms of hyperinsulinemic hypoglycemia including surreptitious insulin administration. No 
standardized treatment regimen exists. 
Objectives: To evaluate an analytic approach to IAS and responses to different treatments. 
Design and Setting: Observational study in the UK Severe Insulin Resistance Service. 
Patients: 6 patients with hyperinsulinemic hypoglycemia and detectable circulating anti-
insulin antibody (IA). 
Main outcome measures: Glycemia, plasma insulin and C-peptide concentrations by 
immunoassay or mass spectrometry (MS). Immunoreactive insulin was determined in the 
context of polyethylene glycol (PEG) precipitation and gel filtration chromatography (GFC). 
IA quantification using enzyme-linked immunosorbent assay (ELISA) and 
radioimmunoassay (RIA), and IA were further characterized using radioligand binding 
studies. 
Results: All patients were diagnosed with IAS (5 IgG, 1 IgA) based on high insulin:C-
peptide ratio, low insulin recovery after PEG precipitation, and GFC evidence of antibody-
bound insulin. Neither ELISA nor RIA result proved diagnostic for every case. MS provided 
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a more robust quantification of insulin in the context of IA. 1 patient was managed 
conservatively, 4 were treated with diazoxide without sustained benefit, and 4 were treated 
with immunosuppression with highly variable responses. IA affinity did not appear to 
influence presentation or prognosis. 
Conclusions: IAS should be considered in patients with hyperinsulinemic hypoglycemia and 
a high insulin:C-peptide ratio. Low insulin recovery on PEG precipitation supports the 
presence of insulin-binding antibodies, with GFC providing definitive confirmation. 
Immunomodulatory therapy should be customized according to individual needs and clinical 
response. 
A case series of insulin autoimmune syndrome highlighting a range of dysglycemic presentations, 
diagnostic challenges and variable responses to therapy. 
Introduction 
Insulin autoimmune syndrome (IAS) features hyperinsulinemic hypoglycemia due to insulin 
autoantibodies in exogenous insulin-naïve individuals (1,2). IAS presents with recurrent 
postabsorptive or fasting hypoglycemia, alternating with postprandial hyperglycemia, due to 
“buffering” by autoantibodies, which sequester insulin in immune complexes during the acute 
phase of insulin secretion, only to release it slowly later, at physiologically inappropriate 
times. 
IAS cannot easily be distinguished on clinical grounds from tumoral or other forms of 
hyperinsulinemic hypoglycemia, which includes hypoglycemia caused by surreptitious 
insulin administration (3). Altered kinetics of insulin clearance in the presence of antibody-
binding also commonly skews insulin:C-peptide molar ratios upwards, sometimes 
dramatically so, as insulin clearance is delayed whilst C-peptide clearance is unaffected. As 
insulin:C-peptide molar ratios are often used to discriminate exogenous from endogenous 
hyperinsulinemic hypoglycemia (4), this raises the risk that maleficent insulin use may be 
erroneously diagnosed, with potentially decisive implications for criminal and child custody 
proceedings. 
Anti-insulin antibody (IA) assays are not standardized, and yield variable, qualitative or 
semi-quantitative results (5) and moreover detection of IA does not prove the presence of 
circulating insulin-antibody complexes (6). Methods currently used to confirm hormone-
antibody complexes include precipitation with polyethylene glycol (PEG), which is not 
specific (7), and gel filtration chromatography (GFC), which may be used in conjunction with 
ex vivo addition of insulin to enhance sensitivity (6). Mass spectrometry (MS) methods now 
offer quantification of insulin (8) that is more robust in the face of anti-hormone antibody 
interference than immunoassay (9). 
Effective use of different immunosuppressive regimens in IAS has been described, 
including prednisolone (10), hydrocortisone (11), azathioprine (12), cyclophosphamide (13), 
mycophenolate mofetil (MMF) (14,15), rituximab (16), and plasmapheresis (17,18), but no 
consensus exists about optimal therapy. We now extend experience by presenting clinical and 
biochemical characteristics of six patients with varying presentations of IAS and responses to 
immunosuppression. 
Materials and Methods 
Patients and blood sampling 
Studies were performed in accordance with the Declaration of Helsinki (2000). Six 
exogenous insulin-naïve patients presenting with hyperinsulinemic hypoglycemia and high 
insulin:C-peptide ratio were evaluated by the UK Severe Insulin Resistance Supraregional 
Assay Service, Cambridge University Hospitals NHS Foundation Trust, Cambridge.  
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Immunoassays and insulin immunocomplex detection 
Blood was collected on ice and plasma/serum rapidly separated and frozen at -80°C. Plasma 
insulin and C-peptide were measured using immunoassay platforms approved for clinical use. 
PEG precipitation studies were performed as previously published (6), with analyte recovery 
taken to be the PEG supernatant insulin concentration expressed as a percentage of insulin 
measured in matched saline-diluted samples. GFC was performed as previously described 
(6). 
Anti-insulin IgG was determined using an in-house human insulin-specific ImmunoCAP® 
enzyme-linked immunosorbent assay (ELISA). IA were also determined using a competitive 
IA radioimmunoassay (RIA) (19). In brief, 5µL of serum, neat or diluted with IA negative 
serum, was incubated with A14-125I-labeled human insulin ± unlabeled synthetic human 
insulin at 40 µmol/L. 125I-IA complexes were precipitated using glycine-blocked Protein A 
Sepharose (PAS), ethanolamine-blocked Protein G Sepharose (PGS) (20), and/or IgA 
agarose.  
IA affinity was assessed in neat and diluted serum (21,22), with immune complexes 
precipitated using a 50:50 mixture of PAS and PGS to include all possible IA-reactive IgG 
antibodies. IC50, Kd (mol/L) were calculated by non-linear regression analysis using a one-
site model (22) (R2 values 0.88-0.99), assuming equal antibody binding by labeled and 
unlabeled insulin. 
Immunosubtraction using anti-human immunoglobulin-agarose 
Synthetic human insulin, diluted in 5% BSA, was added to plasma before 24-hour incubation 
at 24°C. Agarose-conjugated anti-immunoglobulin (anti-human IgA; anti-human IgM; anti-
human IgG) was washed thrice with 0.9% saline and stored at 4°C. Agarose conjugates were 
added to plasma at ratios based on in-house data (volume ratios of agarose-antibody:plasma 
were 5:1 for anti-IgA, 29:20 for anti-IgM, and 32:3 for anti-IgG). IgA antibody−agarose 
experiments for Patient 6 were performed in triplicate. Samples were mixed for 60 minutes 
prior to centrifugation at 13,200g for 15 minutes. To overcome sampling error due to 
increased sample viscosity, agarose supernatant was diluted in saline prior to analysis. Insulin 
recovery was calculated as percentage insulin recovery in agarose supernatant of dilution-
matched plasma. 
Quantitative mass spectrometric analysis of insulin and C-peptide  
Pooled human plasma was fortified with insulin lispro and C-peptide to generate 
concentrations of 8,610 pmol/L to 17 pmol/L and 16,548 pmol/L to 33 pmol/L, respectively. 
250µL of each sample of known peptide concentration, of available patient plasma, and of 
unfortified pooled plasma were transferred to different wells of a 2mL 96-well plate. 5 patient 
and 34 control samples were extracted using a combination of acetonitrile precipitation and 
solid phase extraction-liquid chromatography (23) along with quality control (QC) samples 
and analyzed with two separately extracted sets of calibration samples. MS data were 
acquired from m/z 700-1600, with a resolution of 70,000 and an automatic gain control target 
of 3e6 ions. Insulin and C-peptide calibration curves were generated using m/z values for the 
[M+5H]5+ charge states relating to the monoisotopic (1161.7362) and multiple 13C isotopes of 
human insulin and for the [M+3H]3+ charge state of C-peptide (1007.1783). Calibration 
curves for insulin and C-peptide gave a linear fit with R2 values of 0.995 and 0.994, 
respectively, after correcting for endogenous analyte, and calibration standards and QC 
samples were all within ±25% of expected values. Regression between immunoassay and MS 
control plasma values were linear for insulin (0.8727x-27.025; R2=0.974), and C-peptide 
(1.317x-56.86; R2 = 0.997). 
Results 
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A summary of the clinical characteristics of patients studied and the investigations 
undertaken on initial presentation is given in Table 1. Case histories follow: 
Patient 1 presented after 20 months of shakiness, sweating, pallor, and confusion, 
generally 1-2 hours postprandially, and alleviated by carbohydrate ingestion. She had 
concurrently gained 7kg in weight. On emergency admission plasma glucose concentration 
was 30 mg/dL (1.7 mmol/L) (normal range (NR) 72-110 mg/dL), with concomitantly 
inappropriate plasma immunoassay insulin and C-peptide concentrations of 267 pmol/L (NR 
<60) and 899 pmol/L (NR 174-960) respectively, and a molar ratio of insulin:C-peptide of 
0.30 (NR 0.03-0.25) (24,25). 72-hour fast and mixed meal tolerance test (MMTT) failed to 
solicit hypoglycemia, however a 75g oral glucose tolerance test (OGTT) produced a glucose 
nadir of 39 mg/dL (2.2 mmol/L) (Fig. 1a) at 240 minutes. Continuous glucose monitoring 
system (CGMS) demonstrated labile glycemia including late post-prandial hypoglycemia 
(Fig. 1b). IA were grossly elevated at 722.4 U/mL (NR <0.4) (RiARSR® IAA, Cardiff, UK). 
Gross hyperinsulinemia was confirmed using MS (Table 2). Low insulin recovery 
following PEG precipitation using an immunoassay suggested IA. GFC with and without 
addition of exogenous human insulin showed predominantly high molecular weight (HMW) 
insulin immunoreactivity, confirming IAS (6). IA were positive by ELISA and RIA, the latter 
indicating a high insulin-binding capacity. Competitive insulin-binding studies (Fig. 2) 
suggested a sub-nanomolar dissociation constant (analyzed at ten-fold serum dilution, with a 
two-site model offering the best fit, both sites binding with high affinity). 
Two 1g intravenous methylprednisolone doses were given one day apart monthly for 4 
months, however symptoms continued over the ensuing 2 years with hypoglycemia 
remaining demonstrable on OGTT and CGMS. Rituximab (750 mg/m2 X2) was 
administered, reducing glycemic lability (Fig. 1c) with only two capillary blood glucose 
(CBG) readings <55mg/dL (<3.1 mmol/L) recorded over 9 months following rituximab. At 
this stage, IA concentration had decreased to 153 U/mL (NR<0.4, RiARSR® IAA), and 
fasting plasma insulin and C-peptide concentrations by immunoassay were 173 pmol/L (NR 
<60) and 500 pmol/L (NR 174-960) respectively. 
Patient 2 presented with fasting symptoms of hypoglycemia including syncope. She 
became hypoglycemic after 10 hours of fasting with a venous plasma glucose of 34 mg/dL 
(1.9 mmol/L), and concomitant plasma insulin immunoassay concentration of 68,123 pmol/L, 
C-peptide 3690 pmol/L, and insulin:C-peptide molar ratio of 18 (NR 0.03-0.25). Gross 
hyperinsulinemia was confirmed by immunoassay (Table 2) and low insulin recovery 
following PEG precipitation suggested IA. GFC of plasma showed HMW insulin 
immunoreactivity consistent with insulin-binding antibodies, confirming IAS (Fig. 3a). IAs 
were positive by ELISA and RIA, the latter result consistent with GFC findings of a very 
high insulin-binding capacity. Competitive insulin-binding studies (Fig. 2) suggested a 
nanomolar dissociation constant (analyzed at ten- and fifty-fold dilution). 
Initial diazoxide treatment was ineffective and caused neutropenia, leading to 
discontinuation. Prednisolone 30mg daily was begun with addition of MMF 1.5g daily after 
IAS confirmation. Hypoglycemia resolved over the subsequent 4 weeks, anti-insulin IgG 
falling to 5 mg/L, plasma insulin to 322 pmol/L, and C-peptide to 1,210 pmol/L, although 
insulin recovery after PEG precipitation increased only modestly to 17%. Following 
treatment GFC demonstrated reduction of HMW insulin (Fig. 3b). The patient remained 
euglycemic on maintenance MMF for 12 months before discontinuing immunosuppressive 
therapy with no evidence of recurrence during the twelve months of follow-up to date.  
Patient 3 presented with 2 years of recurrent anxiety, confusion, perioral paraesthesiae 
and generalized diaphoresis on fasting. Typically, she would wake during the night with 
feelings of terror and agitation. These symptoms would swiftly resolve following 
carbohydrate ingestion. Emergency medical attendants had recorded CBG readings of 36 and 
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43 mg/dL (2.0 and 2.4 mmol/L). During inpatient supervised fasting symptomatic 
hypoglycemia was recorded at 4 hours with a venous plasma glucose of 39 mg/dL (2.2 
mmol/L) and paired immunoassay plasma insulin and C-peptide concentrations of 17,800 and 
409 pmol/L respectively, with an insulin to C-peptide molar ratio of 44 (NR 0.03-0.25).  
Hyperinsulinemia was confirmed using MS (Table 2). Insulin measurement by 
immunoassay underestimated total insulin in neat plasma, and was non-linear to dilution, 
with low insulin recovery following PEG precipitation, all suggesting IA. GFC showed 
predominantly HMW insulin immunoreactivity, confirming the diagnosis of IAS (Fig. 3c). IA 
were positive by ELISA and RIA, the latter result consistent with GFC findings of a very 
high insulin-binding capacity. Competitive insulin-binding studies (Fig. 2) suggested a sub-
nanomolar dissociation constant (analyzed at hundred-fold serum dilution). 
Initial diazoxide treatment was ineffective and was discontinued. Prednisolone 60mg 
daily, later changed to dexamethasone 8mg twice daily, was commenced after IAS 
confirmation, with MMF twice daily later added. CGM demonstrated both hyper- and 
hypoglycemia (Fig. 1d). Following nausea and raised serum transaminases, MMF was 
replaced by azathioprine 50 mg twice daily. High-dose steroid treatment for hypoglycemia 
produced Cushing’s syndrome, including agitated depression, and avascular necrosis of the 
hip. Rituximab (1g X2) was administered and dexamethasone weaned to 1mg daily, but no 
evidence of depletion of the pathogenic antibody (Fig. 4a) nor glycemic improvement were 
seen. Plasma exchange (thrice weekly X8), in contrast, led to resolution of hypoglycemia, 
disappearance of serum IA, improvement in insulin immunoassay linearity (Fig. 4b) and an 
increase in insulin recovery after PEG precipitation. Although transient, this proved the 
efficacy of immunodepletion and plasma exchange followed by a course of rituximab (750 
mg/m2 X4) was administered. Despite amelioration of hypoglycemia, euglycemia was not 
achieved, leading to further plasma exchange and administration of rituximab (750 mg/m2 
X4), for recrudescent hypoglycemia six months later. After a further six months, the patient 
was taking azathioprine but no glucocorticoid. She no longer suffered with fasting 
hypoglycemia, but had persistent reactive hypoglycemia, managed with dietetic support in 
combination with acarbose (alpha-glucosidase inhibitor) to limit postprandial insulin 
secretion. 
Patient 4 presented with 9 months of episodic diaphoresis, headache, hunger and 
confusion, attributed to spontaneous hypoglycemia. Three days after initial consultation he 
had a myocardial infarction and coronary artery bypass surgery. Initial plasma immunoassay 
insulin concentration was 1,732 pmol/L, and C-peptide 794 pmol/L during spontaneous 
hypoglycemia. Over two 72-hour fasts a blood glucose nadir of 45 mg/dL (2.5 mmol/L) was 
recorded. MMTT revealed early post challenge hyperglycemia, with a peak concentration of 
232 mg/dL (12.9 mmol/L), and a late glucose nadir of 29 mg/dL (1.6 mmol/L) (Fig. 1e). 
Plasma immunoassay insulin was concomitantly >6,945 pmol/L (C-peptide not measured). 
Glycemic lability was confirmed by CGM (Fig. 1f). 
Gross hyperinsulinemia was confirmed using MS (Table 2). Insulin measurement by 
immunoassay underestimated total insulin in neat plasma, and was non-linear to dilution, 
with very low insulin recovery following PEG precipitation suggesting IA. GFC showed 
predominantly HMW insulin immunoreactivity, confirming IAS (Fig. 3d). IA were strongly 
positive by ELISA but equivocal by RIA, the former result consistent with GFC findings of a 
high insulin-binding capacity. Unlike the low levels of RIA binding with protein A 
immunoprecipitation (Table 2), high levels were demonstrable with protein G that could be 
explained by insulin-binding due to IgG3. Competitive insulin-binding studies (Fig. 2) 
(analyzed in neat serum) suggested a micromolar dissociation constant, although 
interpretation was limited by low baseline binding. 
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Diazoxide (50mg thrice daily) reduced frequency and severity of hypoglycemia, however 
after 6 months lanreotide 60mg subcutaneously was added monthly as hypoglycemia 
continued to compromise quality of life. Lanreotide controlled hypoglycemia but caused 
gastrointestinal side effects leading to its withdrawal. Acarbose was not tolerated. Diazoxide 
was continued at increased dose (100mg thrice daily) for three years with concomitant 
diuretics to manage edema. HbA1c on diazoxide remained around 55 mmol/mol (NR 20-42). 
Immunomodulatory therapy was declined but remains under consideration.  
 Patient 5 presented with recurrent falls associated with cognitive decline. Borderline low 
CBG concentrations at 50 mg/dL (2.8 mmol/L), as well as concentrations as high as 248 
mg/dL (13.8 mmol/L) consistent with diabetes mellitus, were noted during admission 
however no glycopenic symptoms were apparent. Plasma immunoassay insulin 
concentration, at a time when blood glucose concentration was 37 mg/dL (2.1 mmol/L), was 
1,024 pmol/L with concomitant C-peptide of 679 pmol/L and insulin to C-peptide molar ratio 
of 1.51 (NR 0.03-0.25). Gross hyperinsulinemia was confirmed using MS (Table 2). Insulin 
measurement by immunoassay underestimated total insulin in neat plasma, and was non-
linear to dilution, with very low insulin recovery following PEG precipitation suggesting IA. 
GFC showed HMW insulin immunoreactivity, confirming IAS. IA were positive by ELISA 
and RIA, and competitive insulin-binding studies (Fig. 2) (analyzed at ten-fold serum 
dilution) suggested a sub-micromolar dissociation constant. Further investigation and 
treatment was declined, and the patient was discharged to residential care with a CBG meter 
and advice to avoid fasting. Four months later, she was admitted to hospital with reduced 
consciousness and a CBG reading of 23 mg/dL (1.3 mmol/L). Blood glucose normalized with 
intravenous glucose. Prednisolone 10mg daily was commenced and the patient was 
discharged with advice for regular blood glucose monitoring, and glucose gel was provided. 
She has since died. 
Patient 6 presented with two episodes of loss of consciousness due to hypoglycemia. On 
both occasions low CBG was detected, and he was admitted to hospital for emergency 
treatment. He had no family history of diabetes or hypoglycemia. Two 72-hour fasts failed to 
provoke hypoglycemia, with a glucose nadir during the first fast of 72 mg/dL (4.0 mmol/L). 
In contrast, prolonged 75g OGTT produced a glucose nadir of 26 mg/dL (1.4 mmol/L) (Fig. 
1g) with a corresponding immunoassay insulin of 1,285 pmol/L and C-peptide of 1,006 
pmol/L and insulin to C-peptide ratio of 1.28 (NR 0.03-0.25) at 180 minutes after the glucose 
load. This led to loss of consciousness, which was rescued with intravenous glucose. IAS was 
suspected and prednisolone 60mg with diazoxide 300mg daily was commenced. IA were, 
however, within reference limits using two RIA. 
Gross hyperinsulinemia was confirmed using MS (Table 2). Insulin measurement using 
immunoassay underestimated total insulin in neat plasma, was non-linear to dilution, with 
low insulin recovery following PEG precipitation suggesting IA. GFC studies with and 
without preincubation of plasma with exogenous human insulin showed HMW insulin 
immunoreactivity consistent with insulin-binding antibodies, confirming the diagnosis of IAS 
(Fig. 3e). IA were equivocal by ELISA and negative by RIA which was inconsistent with 
GFC findings of a high insulin-binding capacity. To identify the class of the putative IA, 
immunosubtraction studies were performed using antibody class-specific antibodies 
conjugated to agarose. Patient 6 plasma was compared to control plasma with insulin-binding 
IgG, and three plasma samples with no evidence of insulin autoimmunity, all matched for 
insulin concentration. To increase the sensitivity of the method to detect IA, plasma was 
incubated with synthetic human insulin to drive the binding equilibrium in favor of bound 
insulin. Plasma insulin recovery was close to 100% in all cases except for those with anti-
insulin IgG subtracted for IgG, and Patient 6 subtracted for IgA. In both cases recovery fell to 
around 50-60%, indicating the presence of anti-insulin IgA in Patient 6. In keeping with this, 
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no increased precipitation of radiolabel was seen using either protein G or protein A, but 
demonstrably increased precipitation was seen with anti-IgA agarose. The baseline PAS/PGS 
radioligand binding was too low (analyzed in neat serum) to allow reliable calculation of 
binding affinity. 
Prednisolone was reduced to 40mg daily and no further symptomatic hypoglycemia was 
recorded. Four months following diagnosis, during prednisolone treatment, blood tests 
confirmed the continued presence of insulin-binding antibodies. CGM confirmed labile 
glycemia, with matutinal hyperglycemia and postprandial hyperglycemia (Fig. 1h) leading to 
immunodepletion therapy being considered 
Quantitative LC-MS insulin and C-peptide results 
Individual results are shown in Table 2. There was insufficient plasma from patient 2 for 
analysis. Molar ratios of IAS insulin:C-peptide ranged from 3.7 to 8.4, and for 34 control 
plasma samples from 0.2 to 1.5 with one outlier of 0.02. 
Discussion 
IAS has been reported most widely in Japan (1), and despite numerous but scattered reports 
elsewhere, and frequent airing of the diagnostic possibility in forensic investigation of 
suspected insulin poisoning, there is relatively little awareness of the condition in the Western 
Hemisphere amongst endocrinologists. IAS most often presents with hypoglycemia, which 
may be postprandial, postabsorptive or fasting. In this series, the presenting symptoms ranged 
from daytime loss of consciousness to modest symptoms only after overnight fasting. Patients 
1, 4 and 6 displayed reactive hypoglycemia on dynamic testing while in patients 2 and 3 
hypoglycemia was provoked by fasting. Prolonged fasting of patients 1, 4 and 6 did not result 
in hypoglycemia using thresholds aimed at excluding insulinoma, as in some published cases 
of IAS (16,26,27). Four of six patients underwent imaging using modalities including MRI, 
endoscopic ultrasonography and PET/SPECT before IAS was diagnosed. Suggestive 
biochemical evidence for IAS existed in each case, and some imaging may have been 
avoided with earlier access to definitive testing. 
In this series, the first clue to IAS came from high insulin concentrations and insulin:C-
peptide molar ratios in samples drawn during hypoglycemia. Immunoassay results were 
shown to be non-linear to dilution at presentation (linearity improving following plasma 
exchange), and to underestimate MS-detected insulin in neat plasma, consistent with assay 
interference due to the IA competing with the immunoassay antibodies for insulin-binding 
sites (6). Consistent with previous observations (28–31) immunoassay C-peptide 
concentrations, in the five patients in whom it was measured, were reported at hundreds to 
thousands of picomoles per liter concurrent with hypoglycemia. Immunoassay C-peptide 
concentrations in patients 1, 3, 4 and 6 conversely overestimated MS C-peptide more than 
may be expected from assay bias alone (32) possibly due to cross-reacting insulin precursors 
not detected by the MS method. As MS methods are not susceptible to antibody interference 
they are more likely to return a correct value for total insulin concentration in IAS and thus 
increased confidence in the diagnosis. 
IA are a sine qua non of IAS (33), but assay sensitivity and specificity in the diagnosis of 
IAS has not been established. Indeed IA were first described in patients receiving exogenous 
insulin (34,35), with such frequency that in early literature the presence of such antibodies in 
hypoglycemic ostensibly insulin-naïve patients was regarded as nearly diagnostic of 
surreptitious insulin administration (36). They are  now well established in the repertoire of 
autoantibodies used to identify type 1 diabetes (37) and to stratify non diabetic people 
according to risk of autoimmune diabetes (38,39). They may also be detected in healthy 
blood donors or patients with unrelated autoimmune disorders (40–42). Different diagnostic 
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laboratories employ different methods; these are  non-standardized, and assay concordance 
remains poor (5,43) despite longstanding attempts at harmonization (44). In all patients, 
recovery of immunoreactive insulin after PEG precipitation was low and GFC confirmed 
HMW insulin-containing complexes, however not all patients had elevated IA on initial 
testing. In this study ELISA and RIA moreover produced different rankings of the magnitude 
of the results, possibly due to differential effects of high endogenous insulin concentrations. 
Antibody characteristics will also contribute to assay variability: for Patient 4 the ELISA/RIA 
discrepancy may be attributable to underrepresentation of IgG3 in immunoglobulins captured 
by protein A prior to RIA. More strikingly, in Patient 6 equivocal or negative antibody levels 
were determined using four different IA assays, despite convincing GFC evidence of insulin-
antibody complexes. Anti-insulin IgA was ultimately demonstrated by immunosubtraction, 
explaining the discrepancy. Only around 70% of IgA is removed using PEG precipitation (in-
house data), explaining the relatively modest suppression of recovery after PEG precipitation 
in this case, and raising the possibility that PEG precipitation may offer false reassurance in 
the presence of IgA IA. The use of alternative immunoprecipitation methods may increase the 
sensitivity of these tests but offer diminishing returns and increase complexity and cost.  For 
example, further studies using anti- IgA showed Patient 5 also to possess significant IgA IA 
binding of insulin. Unfortunately, there is no failsafe method for immunosubtraction of 
immunoglobulin subclasses. It is tempting to speculate that patients 2 and 3 exhibited 
hypoglycemia principally during fasting due to the high affinity and very high capacity of 
their IA, however antibody capacity and affinity did not appear to correlate with 
physiological abnormality across the whole group studied. 
Hypoglycemia in IAS has been reported to resolve spontaneously in most patients within 
three months (1). The severe hypoglycemia seen in this series, sustained over months or 
years, allied to other reports, demonstrate that this is not always true however. As IAS is 
antibody-mediated, targeting of pathogenic antibodies is rational. In keeping with this 
diazoxide, which targets insulin secretion, showed modest or no benefit. Four patients in this 
series to date were treated with immunomodulatory therapies. Patient 1 was treated with 
glucocorticoids alone over more than 4 months, however intermittent hypoglycemia persisted 
and so therapy with rituximab was used. Patient 6 also failed to experience improvement of 
glycemic lability and immunodepletion therapy is being considered. Patients 2 and 3 were 
both initially treated with glucocorticoids and MMF, however whilst Patient 2 appears to 
have gone into remission relatively quickly, Patient 3 continued to experience severe 
hypoglycemia, despite high-dose glucocorticoids (which caused severe side effects). 
Ultimately, it was necessary to combine plasma exchange with rituximab therapy. 
Collectively, this demonstrates that therapeutic responses are variable.  
In summary, IAS should be considered in cases of spontaneous hypoglycemia with a high 
insulin:C-peptide molar ratio. Measurement of IA is an appropriate screening step, however 
although the IA assays used in this series detected antibodies in five patients, they were 
equivocal or negative in Patient 6, illustrating that IA results are assay-dependent (5). 
Moreover, detection of IA alone is not specific for actionable antibodies (6) meaning that 
further measures to confirm plasma insulin-antibody complexes are required for diagnosis. 
MS-based methods promise to increase diagnostic confidence as they are unaffected by 
antibody-based assay interference. Immunodepletion is warranted in severely affected 
patients. Our series demonstrates that therapeutic responses vary, and so a customized, and 
flexible approach to depleting pathogenic antibodies is required. More standardized 
approaches to IAS diagnosis will facilitate the systematic therapeutic studies required. 
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Figure 1: Variable patterns of dysglycemia of patients studied. (a) Venous plasma 
glucose concentrations during a 75g oral glucose tolerance test (OGTT) at presentation of 
Patient 1; ○ denotes glucose measurements following glucose rescue. The glucose nadir was 
39 mg/dL (2.2 mmol/L). (b) Demonstration of labile glycemia in Patient 1 at presentation by 
Continuous Glucose Monitoring System (CGMS). (c) Demonstration of normoglycemia in 
Patient 1 following immunomodulation therapy. (d) Demonstration of labile glycemia in 
Patient 3 concomitant with glucocorticoid therapy. (e) Demonstration of reactive 
hypoglycemia in Patient 4 at presentation by mixed meal tolerance test. The peak glucose 
concentration was 232 mg/dL (12.9 mmol/L) with glucose nadir at 300 minutes of 29 mg/dL 
(1.6 mmol/L). (f) Demonstration of reactive and nocturnal hypoglycemia in Patient 4 at 
presentation by CGMS. (g) Demonstration of reactive hypoglycemia in Patient 6 at 
presentation by 75g OGTT. The glucose nadir was 26 mg/dL (1.4 mmol/L). (h) 
Demonstration of labile glycemia in Patient 6 at presentation by CGMS. 
Figure 2 Displacement curves for samples from the Patient 1-5 serum at various dilutions in 
antibody-negative serum following competitive displacement with unlabeled human insulin. 
Although identified as low affinity (4.1x10-7 mol/L), Patient 6 plasma was considered 
unreliable because baseline levels of insulin binding were very low. Serum was diluted as 
follows, Patient 1: 10-fold; Patient 2: 50-fold; Patient 3: 100-fold; Patient 4: neat; Patient 5: 
10-fold. 
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Figure 3 Demonstration of insulin-antibody complexes using gel filtration 
chromatography (GFC). Results of insulin assay after GFC of non-fasting plasma. Elution 
volumes of immunoglobulin (Ig), albumin (Alb) and monomeric insulin (mIns) are shown. 
Results are shown for Patient 2 at (a) presentation (pre-therapy), and (b) with and without 
preincubation of plasma with exogenous insulin post-therapy, and with and without 
preincubation of plasma with exogenous insulin at presentation for (c) Patient 3, (d) Patient 4, 
and (e) Patient 6. 
Figure 4: Response of biochemical markers to therapy in Patient 3. (a) Cumulative 
results for Patient 3 over course of treatments, including mycophenolate mofetil (MMF); 
azathioprine (AZA), prednisolone (Pr), dexamethasone (Dex), rituximab (R), and plasma 
exchange (PEx), showing anti-insulin IgG concentrations (in-house human insulin specific 
ImmunoCAP®) and immunoassay insulin recovery following PEG precipitation over time. 
(b) Effect of plasma exchange on insulin immunoassay linearity to dilution. Calculated 
insulin concentration plotted against plasma dilution of Patient 3 plasma before plasma 
exchange and following cycle 1 and cycle 9. 
Table 1: Clinical characteristics and initial investigation of patents studied. 
*Hypoglycemia with inappropriately elevated plasma insulin were inclusion criteria for this 
study so are excluded from the table. BMI = body mass index; CGMS = continuous glucose 
monitoring system; CT = computerized tomography; GAD = glutamic acid decarboxylase; α-
INSR = anti-insulin receptor; IA2 = islet antigen-2; MMTT = mixed meal tolerance test; MRI 
= magnetic resonance imaging; OGTT = oral glucose tolerance test; PET = positron emission 
tomography; SPECT = single-photon emission computerized tomography; SU = 
sulfonylurea; US = ultrasound   
Patient 
Age 
(yea
rs) 
Sex 
Et
hni
cit
y 
BMI (kg/m2) Pre-existing diagnoses Medications Presentation 
Investigatio
ns with 
abnormal 
results* 
Investi
gations 
with 
normal 
results
* 
Nega
tive 
imag
ing 
1 56 
Fe
mal
e 
Ca
uca
sia
n 
26.2 
Autoimmune 
hypothyroidis
m 
None Postprandial hypoglycemia 
OGTT nadir 
39 mg/dL 
(2.2 mmol/L) 
HbA1c CT 
abdo
men 
Asthma 
CGMS 72-hour 
fast 
nadir 
59 
mg/dL 
(3.3 
mmol/L
) 
MRI 
abdo
men 
Factor XI 
deficiency 
 MMTT Endo
scopi
c US 
 
 SU 
screen 
 
 
 α-islet, 
α-
GAD65
, α-IA2, 
α-INSR 
autoanti
bodies 
 
2 52 
Fe
mal
e 
Th
ai 35.0 None None 
Fasting 
hypoglycemia 
 SU 
screen 
α-INSR 
autoanti
bodies 
68Ga-
DOT
ATA
TE 
PET/
CT 
3 28 Fe Ca 25.1 None None Fasting  HbA1c 68Ga-
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mal
e 
uca
sia
n 
hypoglycemia SU 
screen 
DOT
ATA
TE 
PET/
CT 
4 76 Male 
Ca
uca
sia
n 
29.5 
Type 2 
diabetes 
Ischemic heart 
disease Parotid 
pleomorphic 
adenoma 
Glaucoma 
Spironolacto
ne 
Furosemide 
Losartan 
Aspirin 
Bisoprolol 
Atorvastatin 
Omeprazole 
Fluoxetine 
Postprandial/ 
nocturnal 
hypoglycemia 
MMTT nadir 
29 mg/dL 
(1.6 mmol/L) 
72-hour 
fast 
nadir 
45 
mg/dL 
(2.5 
mmol/L
) 
MRI 
abdo
men 
CGMS Endo
scopi
c US 
 Octre
otide 
SPE
CT 
 
18F-
Deox
ygluc
ose-
PET 
5 89 
Fe
mal
e 
Ca
uca
sia
n 
19.4 Small B cell lymphoma 
Furosemide 
Fexofenadine 
Ferrous 
fumarate 
Low capillary 
blood glucose 
readings 
 Short 
Synacth
en® test 
nil 
6 50 Male 
Ca
uca
sia
n 
22.3 None None Postprandial hypoglycemia 
OGTT nadir 
26 mg/dL 
(1.4 mmol/L) 
72-hour 
fast 
nadir 
72 
mg/dL 
(4.0 
mmol/L
) 
CT 
abdo
men 
SU 
screen 
Table 2: Biochemical evaluation of non-fasting plasma in a single specialized center. 
GFC = gel filtration chromatography; HMW = high molecular weight; IA = anti-insulin 
antibody; Kd = dissociation constant; MS = mass spectrometry; PEG = polyethylene glycol. * 
The reference range used for the anti-insulin IgG assay was provided by a reference 
laboratory using the same method (Sheffield Protein Reference Unit, Sheffield, UK).  Testing 
28 of the 34 control samples used in the quantitative mass spectrometric analysis of insulin 
and C-peptide yielded a 75% percentile insulin antibody concentration of 4.8 mg/L. 
Patient 
MS 
insul
in 
(pm
ol/L) 
Immunoassay 
insulin 
pmol/L (<60) Insulin 
recovery 
after PEG 
precipitati
on % 
(>102) 
GFC 
of 
insuli
n 
Anti-
insuli
n 
IgG 
mg/L 
(0-
5)* 
IA 
cIA 
units 
(<0.2) 
Kd 
mol/L 
MS 
C-
pepti
de 
pmol/
L 
Immunoas
say C-
peptide 
pmol/L 
(174-960) 
MS 
Insuli
n: C-
peptid
e 
molar 
ratio 
(0.2-
1.5) 
Immunoas
say insulin: 
C-peptide 
molar ratio 
(0.03-0.25) 
Dilution ratio 
(Plasma:dilue
nt) 
1:0 1:4 
1 5,278 
>3,00
0 7,020 8 
HM
W 
insuli
n 
prese
nt 
16 2,408 3.42x10-10 1,428 3,750 3.7 1.9 
2 - >3,000 
11,58
5 6 
HM
W 
insuli
n 
prese
nt 
38 8,738 1.16 
x10-9 - 5,580 - 2.1 
3 1,583 782 4,601 9 
HM
W 
insuli
n 
prese
nt 
11 >10,000 
4.68 
x10-10 215 2,380 7.4 0.3 
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4 2,912 1,340 3,912 11 
HM
W 
insuli
n 
prese
nt 
>200 4.0 6.55 
x10-6 348 1,190 8.4 1.1 
5 6,589 2,781 7,805 3 
HM
W 
insuli
n 
prese
nt 
89 300 8.55 
x10-7 880 3,110 7.5 0.9 
6 4,012 2,906 5,630 65 
HM
W 
insuli
n 
prese
nt 
5 0.1 - 750 3,280 5.4 0.9 
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